9 / 42
Kaplan-Meier Estimate of OS: Updated Analysis
a
Nominal
P
value.
NR, not reached.
Data cutoff: July 10, 2017.
Events, n HR (95% CI)
Pembrolizumab
73
0.63
(0.47–0.86)
P
= 0.002
a
Chemotherapy
96
0
3
6
9
1 2
1 5
1 8
2 1
2 4
2 7
3 0
3 3
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
T im e , m o n th s
O S , %
P e m b r o 1 5 4
1 3 6
1 2 1
1 1 2
1 0 6
9 6
8 9
8 3
5 2
2 2
5
0
C h e m o 1 5 1
1 2 3
1 0 7
8 8
8 0
7 0
6 1
5 5
3 1
1 6
5
0
N o . a t r is k
Median (95% CI)
30.0 mo (18.3 mo–NR)
14.2 mo (9.8 mo–19.0 mo)
70.3%
54.8%
51.5%
34.5%
2 ys OS
51.5% vs 34.5%
HR 0.63
62.3% Crossover
Brahmer et al. WCLC 201